US Patent

US7943788 — Glucopyranoside compound

Composition of Matter · Assigned to Mitsubishi Tanabe Pharma Corp · Expires 2027-07-14 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a glucopyranoside compound with a specific molecular structure.

USPTO Abstract

A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US7943788
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-07-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Mitsubishi Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.